Featured Research

from universities, journals, and other organizations

Novel approach to acute COPD illness

Date:
September 6, 2011
Source:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Summary:
A new study that should help improve the condition for millions of individuals who suffer from chronic obstructive pulmonary disease (COPD). The study reveals that adding a common antibiotic - azithromycin -- to the usual daily treatment for COPD reduced the occurrence of acute exacerbations by 27% and tended to improve the quality of life for COPD patients.

Richard Casaburi, Ph.D., M.D., principal investigator at Los Angeles Biomedical Research Institute (LA BioMed), is co-author of a recent study that should help improve the condition for the millions of individuals who suffer from chronic obstructive pulmonary disease, better known as COPD. The results of the study reveal that adding a common antibiotic -- azithromycin -- to the usual daily treatment for COPD reduced the occurrence of acute exacerbations by 27% and tended to improve the quality of life for COPD patients.

Related Articles


"This important study adds to a growing number of approaches that reduce the frequency of COPD illnesses," said Dr. Casaburi. "Together, they promise COPD patients who avail themselves of readily-available therapies substantially reduced risk of acute lung illnesses. This has the potential to reduce the misery this disease brings and can also can bring down medical costs, as more than half of COPD costs are related to hospitalization for COPD-related illnesses."

COPD is a progressive disease of the lungs that affects about 24 million people in the United States and is now the third leading cause of death in this country. Many patients experience acute COPD-related illnesses ("exacerbations"), which are sudden onsets of worsened cough, wheeze, and labored breathing that are typically induced by bacterial and/or viral infection. Previous research had suggested that the antibiotic azithromycin might decrease COPD exacerbations, but this study was the first to enroll a large number of COPD patients and treat exacerbations with this drug over a full year. Participants had a history of exacerbations in the previous year or needed oxygen therapy.

At 10 regional centers around the United States, the study recruited 558 study participants who took 250 mg of azithromycin daily for a year, in addition to their usual care. They averaged 1.48 acute COPD exacerbations annually, compared to 1.83 exacerbations for the 559 participants who received traditional care without azithromycin. The participants taking azithromycin also tended to report more favorable breathing ability and overall well-being.

Dr. Casaburi leads the Rehabilitation Clinical Trials Center, where over 50 research studies have been performed aimed at improving the lives of patients with COPD. While there is currently no cure, a combination of drugs and lifestyle changes can help manage COPD symptoms.

The results of the study, funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, appeared in the Aug. 25 issue of the New England Journal of Medicine. This study was conducted by the COPD Clinical Research Network (CCRN), an NHLBI-funded consortium of research centers located throughout the U.S. that was established to study new treatments for COPD.


Story Source:

The above story is based on materials provided by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). Note: Materials may be edited for content and length.


Journal Reference:

  1. Richard K. Albert, John Connett, William C. Bailey, Richard Casaburi, J. Allen D. Cooper, Gerard J. Criner, Jeffrey L. Curtis, Mark T. Dransfield, MeiLan K. Han, Stephen C. Lazarus, Barry Make, Nathaniel Marchetti, Fernando J. Martinez, Nancy E. Madinger, Charlene McEvoy, Dennis E. Niewoehner, Janos Porsasz, Connie S. Price, John Reilly, Paul D. Scanlon, Frank C. Sciurba, Steven M. Scharf, George R. Washko, Prescott G. Woodruff, Nicholas R. Anthonisen. Azithromycin for Prevention of Exacerbations of COPD. New England Journal of Medicine, 2011; 365 (8): 689 DOI: 10.1056/NEJMoa1104623

Cite This Page:

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). "Novel approach to acute COPD illness." ScienceDaily. ScienceDaily, 6 September 2011. <www.sciencedaily.com/releases/2011/09/110906102608.htm>.
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). (2011, September 6). Novel approach to acute COPD illness. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2011/09/110906102608.htm
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). "Novel approach to acute COPD illness." ScienceDaily. www.sciencedaily.com/releases/2011/09/110906102608.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

More Coverage


Commonly Prescribed Antibiotic Reduces Acute COPD Attacks; Study Finds Azithromycin Lowers Frequency and Severity of Flare-Ups

Aug. 24, 2011 Adding a common antibiotic to the usual daily treatment regimen for chronic obstructive pulmonary disease (COPD) can reduce the occurrence of acute exacerbations and improve quality of life, reports ... read more

Common Antibiotic Helps Lethal Lung Disease

Aug. 29, 2011 A common antibiotic can help reduce the severe wheezing and other acute symptoms of chronic obstructive pulmonary disease, according to a large new ... read more

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins